Among those taking prescription medications at the onset of the study, 65% ceased their use of opioids, 60% stopped using antidepressants, and 58% ceased their use of anticonvulsants.
Region: Germany
Investigators concluded that medical cannabis can “safely and significantly lower the consumption of co-medicated opioids, even at low dosages.”
Investigators concluded, “CBM therapy should be included as first line therapy for the patient groups considered due to the significant prolongation of survival time.”
Following at least twice-daily treatment with Nabiximols, the patient experienced a “marked tic reduction … without experiencing relevant side effects.”
Investigators concluded, "In summary, we find no evidence to support the presumption that cannabis consumption leads to a decline in neurocognitive ability."
Investigators concluded, “[T]here is no clear overall relationship with THC blood or serum levels and driving skills or crash risk.”
Nearly six-out-of-ten subjects reported improvements in their symptoms, with 22 percent of patients reporting that their condition was “notably improved.”
"Results suggest that MC might be helpful for selected PD patients with insufficient symptom relief despite their usual anti-parkinsonian medication."